COLchicine and Thiamine in Heart Failure Due to Ischemic Heart Disease
Status:
Not yet recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
The goal of this 2x2 factorial clinical trial is to test the efficacy of i) colchicine, and
ii) thiamine in heart failure (HF) secondary to ischemic heart disease. The main questions it
aims to answer are:
- Does colchicine reduce the risk of cardiovascular (CV) death, a HF event, or an ischemic
CV event
- Does thiamine reduce the risk of cardiovascular (CV) death, or a HF event
Participants will undergo the following procedures:
- Run-in: All participants will receive colchicine 0.5 mg daily to assess drug tolerance
over a 3-4 week period.
- Randomization: If colchicine is tolerated during run-in, eligible participants will be
randomized in a 2x2 factorial design to receive i) colchicine 0.5mg daily or placebo,
and ii) thiamine 300mg daily or no thiamine.
- Follow-up: Clinical outcomes, side effects, adverse events, and drug adherence will be
captured during follow-up
Phase:
Phase 3
Details
Lead Sponsor:
Hamilton Health Sciences Corporation
Collaborators:
Canadian Institutes of Health Research (CIHR) Population Health Research Institute